FOR IMMEDIATE RELEASE
Nerbio’s iTOF® Becomes the First FDA-Cleared App-Controlled Neuromuscular Blockade Monitor
San Jose, CA — 05/12/2025 — Nerbio Medical Software Platforms, Inc., a leader in intelligent patient monitoring solutions, proudly announces that its iTOF® device has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone marks iTOF as the world’s first wireless, app-controlled quantitative neuromuscular blockade (NMB) monitoring device to achieve FDA clearance
Designed to modernize perioperative care, the iTOF system integrates a Bluetooth-enabled nerve stimulator with a user-friendly mobile application, offering clinicians precise, real-time monitoring of neuromuscular function. The device supports multiple stimulation modes, including Train-of-Four (TOF), Post-Tetanic Count (PTC), and Double Burst Stimulation (DBS), ensuring comprehensive assessment capabilities.
Key Benefits of iTOF:
Enhanced Efficiency: Clinical use of iTOF has demonstrated a 10% improvement in operating room turnover and a 30% reduction in the use of neuromuscular blockers and reversal agents.
Improved Patient Safety: Hospitals report up to 70% fewer residual blockade complications, aligning with American Society of Anesthesiologists (ASA) guidelines.
Cost-Effective Solution: With a subscription model as low as $1 per day, iTOF eliminates disposable costs and capital expenditures, offering a full replacement warranty.
AI-Assisted Monitoring: The system features voice-guided prompts and AI-driven assistance, enhancing decision-making and reducing the potential for human error.
“The FDA clearance of iTOF represents a significant advancement in neuromuscular monitoring,” said Ken Leonard, Chief Innovation Officer at Nerbio. “Our goal is to provide clinicians with accessible, accurate, and intelligent tools that enhance patient outcomes and streamline perioperative workflows.”
iTOF is currently in use across various international healthcare settings, including hospitals in Chile, Colombia, and India, with over 35,000 cases reported. The device’s portability, ease of use, and integration capabilities make it a valuable asset in both operating rooms and critical care units.
About Nerbio Medical Software Platforms, Inc.:
Founded in 2020 and headquartered in San Jose, California, Nerbio is dedicated to revolutionizing in-hospital patient monitoring through the integration of mobile technology and artificial intelligence. The company’s flagship product, iTOF®, exemplifies its commitment to innovation, safety, and cost-effectiveness in medical device solutions.
LinkedIn
Media Contact:
Ken Leonard
Chief Innovation Officer
Nerbio Medical Software Platforms, Inc.
Phone: +1 (408) 809 3296
Email: [email protected]
For more information, visit www.nerbio.com.
###
